Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 119 Carcinoma, Hepatocellular 69 Ovarian Neoplasms 62 Neoplasms 36 Carcinoma, Non-Small-Cell Lung 34 Fallopian Tube Neoplasms 29 Brain Neoplasms 24 Glioblastoma 22 Colonic Neoplasms 21 Breast Neoplasms 19 Neoplasm Metastasis 18 Endometrial Neoplasms 18 Stomach Neoplasms 15 Uterine Cervical Neoplasms 14 Rectal Neoplasms 14 Lung Neoplasms 14 Liver Neoplasms 11 Triple Negative Breast Neoplasms 10 Melanoma 8 Glioma 8 Carcinoma, Renal Cell 8 Carcinoma, Ovarian Epithelial 8 Biliary Tract Neoplasms 8 Colorectal Cancer Metastatic 7 Squamous Cell Carcinoma of Head and Neck 6 Recurrence 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Gastrointestinal Neoplasms 6 Advanced Solid Tumors 6 Small Cell Lung Carcinoma 5

Interventions

atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × Bevacizumab × 1 year × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡